©2022 Stanford Medicine
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Not Recruiting
Trial ID: NCT00958841,29,30,27555
Purpose
This study will assess the effectiveness and safety of pasireotide long-acting release in
patients who have rare tumors of neuroendocrine origin.
Official Title
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
Stanford Investigator(s)
Y. Joyce Liao, MD, PhD
Professor of Ophthalmology and of Neurology
Eligibility
Inclusion Criteria:
- Male and Female Patients at least 18 years old
- Patient who have rare tumors of neuroendocrine origin, such as tumors of the:
1. pancreas
2. pituitary glands
3. Nelson syndrome
4. ectopic-ACTH secreting tumor
- Patients who have failed standard of care treatment or for whom no standard of care
treatment exist
- Signed Informed Consent
Exclusion Criteria:
- Patients with active gallbladder disease
- Patients with any ongoing or planned anti-neoplastic or interferon therapy
- Poorly controlled diabetes mellitus
- Female patients who are pregnant or lactating, or are of childbearing potential and
not practicing a medically acceptable method of birth control
Other protocol-defined inclusion/exclusion criteria may apply.
Intervention(s):
drug: Pasireotide LAR
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061